The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC).
 
Regina Barragan-Carrillo
No Relationships to Disclose
 
Kai Dallas
No Relationships to Disclose
 
Abhishek Tripathi
Honoraria - Cardinal Health; Targeted Oncology; Urology times
Consulting or Advisory Role - Deka Biosciences; EMD Serono; Exelixis; Exelixis; Foundation Medicine; Genzyme; Pfizer; Seagen
Research Funding - Aravive (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Corvus Pharmaceuticals (Inst); EMD Serono (Inst); Exact Sciences (Inst); Exelixis (Inst); Pfizer (Inst); WindMIL (Inst)
 
Ameish Govindarajan
No Relationships to Disclose
 
Zeynep Busra Zengin
No Relationships to Disclose
 
Luis A Meza
No Relationships to Disclose
 
Errol James Philip
No Relationships to Disclose
 
Daniela V. Castro
No Relationships to Disclose
 
Alexander Chehrazi-Raffle
No Relationships to Disclose
 
Neal Chawla
No Relationships to Disclose
 
Joann Hsu
No Relationships to Disclose
 
Nazli Dizman
Consulting or Advisory Role - Vivreon Biosciences
 
Karyn Eilber
No Relationships to Disclose
 
Cristiane Decat Bergerot
No Relationships to Disclose
 
Sumanta Monty Pal
Research Funding - Allogene Therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Roche